Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
News|Articles|June 18, 2025
Pharmacy Practice in Focus: Oncology
- June 2025
- Volume 7
- Issue 4
Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Author(s)Klara Kim, PharmD
Fact checked by: Luke Halpern, Associate Editor
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Advertisement
Advertisement
Klara Kim, PharmD, will present her encore abstract, “Clinical Manifestations of Acute and Chronic Graft-vs-Host Disease With Posttransplant Cyclophosphamide in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation,” at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20.
Related to this article
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement